Alcon Inc. reports developments in eye care through its Surgical and Vision Care businesses. Company news commonly covers quarterly results, constant-currency sales trends, product-launch momentum and portfolio updates across cataract and vitreoretinal surgical systems, intraocular lenses, contact lenses, lens-care products and ocular health.
Recurring updates also include launches and milestones for products such as Clareon, PanOptix, Vivity, TOTAL30, Precision7, Tryptyr and Unity, along with annual general meeting items, board elections, compensation votes, dividends, share repurchase authorizations, acquisitions, integration costs, R&D spending and other governance or capital-allocation actions.
Yunqi Capital, a 5.1% stakeholder in STAAR Surgical Company (NASDAQ:STAA), has announced its opposition to STAAR's proposed sale to Alcon (SIX/NYSE:ALC) at $28 per share. As STAAR's sixth-largest shareholder with 2,500,061 shares, Yunqi Capital argues that the deal significantly undervalues the company.
The Hong Kong-based investment firm criticizes the Board's decision on three main grounds: (1) failure to conduct a thorough sales process by engaging only with Alcon, (2) an overly pessimistic view of China's market prospects, and (3) inadequate deal valuation, noting the $28 offer represents a 49% discount from Alcon's original October 2024 offer of $55 per share.
Yunqi Capital intends to vote against the merger and urges other shareholders to do the same, aligning with Broadwood Partners (27.4% stockholder) in opposing the transaction.
STAAR Surgical (NASDAQ: STAA), a leader in phakic IOLs, has announced its Board's unanimous support for the proposed merger with Alcon (SIX/NYSE: ALC) at $28.00 per share in cash. The merger represents significant premiums: 51% to the pre-announcement closing price and 59% to the 90-day VWAP.
The company will hold a Special Meeting of Stockholders on October 23, 2025, at 8:30 a.m. PT for shareholders to vote on the merger agreement. The Board strongly recommends voting "FOR" the merger, citing STAAR's lower growth rate, competitive challenges, and declining sales trends in China as key factors making the Alcon deal the best path forward for stockholders.
Alcon (NYSE:ALC) announced significant efficiency improvements with their UNITY Vitreoretinal Cataract System (VCS) compared to existing systems. Two key studies demonstrated superior performance: The first study (n=179) showed 16% overall workflow efficiency gains in vitreoretinal surgery, with 33% faster console set-up and 38% quicker tear-down times versus CONSTELLATION Vision System.
The second study (n=303) revealed that UNITY VCS reduces cataract surgery turnover time by 6% and delivers 35% less total energy into the eye compared to CENTURION Vision System. These improvements are particularly significant given the projected 46.9% increase in AMD patients by 2040 and the global 12% decline in ophthalmologists.
Alcon (NYSE:ALC), the global eye care leader, showcased significant innovations at the 43rd ESCRS Congress in Copenhagen. The company introduced three major technologies now available in Europe: the UNITY Vitreoretinal Cataract System (VCS), Clareon Vivity intraocular lens (IOL), and Voyager DSLT for glaucoma treatment.
The company will present over 40 studies demonstrating the benefits of their technologies, including new data on Vivity IOLs showing positive outcomes in patients with special considerations. Key findings include reduced breakthrough pain medication use and less patient discomfort when performing cataract surgery at more physiologic IOP with CENTURION. Additionally, Alcon launched Intelligent Service Solutions (ISS) globally to maximize customer productivity through remote diagnostics and software updates.
Alcon (NYSE:ALC), the global leader in eye care, announced that CEO David Endicott will present at the 2025 Baird Global Healthcare Conference on September 9, 2025, at 9:05 a.m. ET. The presentation will be accessible via live webcast on the company's investor relations website.
Alcon serves over 260 million people in more than 140 countries annually through its Surgical and Vision Care products, focusing on conditions like cataracts, glaucoma, retinal diseases, and refractive errors. The company employs over 25,000 associates and maintains a 75-year heritage in eye care innovation.
Alcon (NYSE:ALC) reported Q2 2025 results with sales of $2.6 billion, up 4% on a reported basis and 3% in constant currency. The company posted diluted EPS of $0.35 and core diluted EPS of $0.76.
Key highlights include the successful US launch of Tryptyr, a first-in-class dry eye treatment, and the announced acquisition of STAAR Surgical to expand Alcon's myopia correction portfolio. The company generated $889 million in operating cash flow and returned $287 million to shareholders.
For 2025, Alcon updated its outlook, reducing net sales guidance to $10.3-10.4 billion (4-5% growth) and core operating margin to 19.5-20.5%, while maintaining core diluted EPS guidance of $3.05-3.15.
Alcon (NYSE:ALC), the global eye care leader, announced its participation in the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting in Ahmedabad, India from August 21-23, 2025. The company will showcase four symposia, present 10 medical affairs scientific exchange presentations, and feature a hands-on experience zone.
Key highlights include new data on Vivity®, an Extended Depth of Focus (EDOF) intraocular lens, supported by over 10 clinical studies involving more than 700 patients. The company will also present research on cataract surgery performed at physiologic IOP in patients with diabetic retinopathy. Additionally, Alcon will officially introduce UNITY VCS (Vitreoretinal Cataract System) and UNITY CS (Cataract System), their next-generation Phaco/Vit platform, to the Indian market.
Alcon (SIX/NYSE: ALC) has entered into a definitive merger agreement to acquire STAAR Surgical (NASDAQ: STAA) for $28 per share in cash, representing a total equity value of approximately $1.5 billion. The deal offers a 59% premium to STAAR's 90-day VWAP.
The acquisition includes STAAR's EVO family of Implantable Collamer® Lenses (ICL), which provides vision correction for moderate to high myopia patients. This strategic move enhances Alcon's surgical vision correction portfolio, particularly targeting the growing myopia market, expected to affect 50% of the world's population by 2050.
The transaction is expected to close within 6-12 months, subject to regulatory and STAAR shareholder approval, and become earnings accretive in year two. Alcon plans to finance the acquisition through short- and long-term credit facilities.
Alcon (NYSE:ALC) has received Health Canada approval for its UNITY® Vitreoretinal Cataract System (VCS), marking the first innovation from its Unity portfolio. The breakthrough surgical technology combines vitreoretinal and cataract surgical capabilities in one integrated platform.
The system delivers significant improvements over Alcon's current CONSTELLATION® and CENTURION® systems, featuring up to 2x faster nucleus removal with 40% less energy, and the world's fastest vitrectomy probe at 30,000 cuts per minute. The platform includes a novel phacoemulsification modality and a first-of-its-kind phaco handpiece that estimates incision site temperature.
Following successful testing with over 200 surgeons from 30+ countries, Unity VCS is scheduled for commercial launch in early 2026.
Alcon (SIX/NYSE: ALC) announced its intention to acquire LumiThera, Inc. and its photobiomodulation (PBM) device for treating early and intermediate dry Age-Related Macular Degeneration (AMD). The PBM device, which received FDA authorization in November 2024 and CE Mark in November 2018, is the first technology demonstrating meaningful visual improvement in dry AMD patients over two years of treatment.
The pivotal LIGHTSITE III study showed significant results: 88% of patients maintained or gained vision, and 64% gained at least one line of visual acuity. The device is currently available in Europe, Latin America, Singapore, the UK, and the US. The acquisition, excluding LumiThera's diagnostic devices, is expected to close in Q3 2025, subject to customary conditions and shareholder approval.